Immuneering (US:IMRX)2025-03-20 20:07Financial Performance - Net loss attributable to common stockholders for Q4 2024 was $18.1 million, or $0.58 per share, compared to a net loss of $15.1 million, or $0.52 per share, in Q4 2023[10] - Full-year net loss attributable to common stockholders for 2024 was $61.0 million, or $2.04 per share, compared to $53.5 million, or $1.88 per share, for 2023[10] - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $36.1 million, down from $85.7 million as of December 31, 2023[10] Research and Development - Reported an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients[3] - Research and Development (R&D) expenses for Q4 2024 were $14.9 million, compared to $11.9 million in Q4 2023, with full-year R&D expenses of $48.0 million versus $41.6 million in 2023[10] - Initiation of multiple Phase 2a arms of IMM-1-104 in combination with various inhibitors planned for 2025[10] - FDA granted Fast Track designation for IMM-1-104 in advanced melanoma and Orphan Drug designation for pancreatic cancer[6][7] Management and Leadership - New Chief Medical Officer, Dr. Igor Matushansky, appointed to oversee clinical activities and development programs[4] Assets and Liabilities - Total assets decreased from $102,584,538 in December 31, 2023 to $52,714,413 in December 31, 2024, representing a decline of approximately 48.5%[20] - Current assets fell from $89,083,669 in December 31, 2023 to $39,587,569 in December 31, 2024, a decrease of about 55.6%[20] - Total liabilities reduced from $12,008,355 in December 31, 2023 to $11,328,187 in December 31, 2024, a decrease of about 5.7%[20] - Stockholders' equity decreased from $90,576,183 to $41,386,226, reflecting a decline of approximately 54.4%[20] - The accumulated deficit increased from $(163,258,578) to $(224,295,186), indicating a worsening of approximately 37.4%[20] Capital Structure - Additional paid-in capital rose from $253,806,267 to $265,650,362, an increase of about 4.7%[20] - Class A common stock shares issued increased from 29,271,629 to 31,050,448, representing a growth of about 6.1%[20] - Cash runway extended into 2026, supported by recent funding activities[9] - General and Administrative (G&A) expenses for Q4 2024 were $3.7 million, down from $4.4 million in Q4 2023, with full-year G&A expenses of $16.1 million compared to $16.8 million in 2023[10] - Total current liabilities slightly decreased from $7,845,503 to $7,503,768, a reduction of approximately 4.4%[20] - Lease liabilities, net of current portion decreased from $4,162,852 to $3,824,419, a decline of approximately 8.1%[20] - Cash and cash equivalents decreased significantly from $59,405,817 to $36,144,720, a drop of approximately 39.0%[20]